Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

NCT02060253 ↗

Phase 1 Completed 9 enrolled Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab New York University Cancer Institute · collab Synta Pharmaceuticals Corp. · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of ganetespib when given with paclitaxel, trastuzumab and pertuzumab in treating patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC).

Timeline

Start: 2014-04
Primary completion: 2018-06
Completion: 2018-06

Publications

Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, Cadoo K, Speyer J, D'Andrea G, Adams S, Patil S, Haque S, O'Neill T, Friedman K, Esteva FJ, Hudis C, Modi S. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Res. 2017 Aug 2;19(1):89. doi: 10.1186/s13058-017-0879-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ganetespib	Small molecule	100 mg/m2	Intravenous
Subject	Ganetespib	Small molecule	125 mg/m2	Intravenous
Subject	Ganetespib	Small molecule	150 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	80 mg/m2	Intravenous
Subject	Pertuzumab	Monoclonal antibody	—	Intravenous
Background	Trastuzumab	Monoclonal antibody	2 mg/kg	Intravenous

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Summary

Timeline

Publications

Drugs

Indications